BioWorld

Jan. 28, 2009

CVT Rejects $1B Acquisition Offer from Partner Astellas

Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today) Read More

Theravance Files Telavancin NDA for Hospital-Acquired Pneumonia

Obama Election Called End of 'Sad Chapter' for Science

Mixed Bag of Pipeline News for Amgen as Earnings Fall Short

Drugmakers Slow to Personalized Medicine Risk Market Share

UK Report on Start-ups Calls for New Source of Funding

NitroMed Agrees to Deerfield Sale, but also Vows to Shop Around

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 29, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...